



## Pliant Therapeutics to Present Data at The Liver Meeting® 2020

November 9, 2020

SOUTH SAN FRANCISCO, Calif., Nov. 9, 2020 /PRNewswire/ -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today announced a poster presentation at The Liver Meeting® 2020 hosted by the American Association for the Study of Liver Diseases (AASLD) to be held virtually November 13 – 16, 2020.



Details for the poster presentation at The Liver Meeting are as follows:

**Poster Title:** [Profiling Fibrosis Regression in a Rat Model of Non-Alcoholic Steatohepatitis](#) (Abstract #0321)

**Session:** Basic Fibrosis Research and Stellate Cell Biology

**Time/Date:** Friday, November 13, 2020: 6:00 AM – 11:55 PM EDT

The presentation is available to registered participants via the [AASLD 2020 website](#). The poster will be available on the Pliant Therapeutics website, under the "Our Science" section, at [www.pliantrx.com](http://www.pliantrx.com) on November 13.

### About Pliant Therapeutics, Inc.

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of  $\alpha_v\beta_6$  and  $\alpha_v\beta_1$  integrins that is in development for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 for the treatment of IPF and PSC. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of  $\alpha_v\beta_1$  for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit [www.pliantrx.com](http://www.pliantrx.com) and follow us on [Twitter](#), [LinkedIn](#), and [Facebook](#).

### Investor and Media Contact:

Christopher Keenan

Vice President, Investor Relations and Corporate Communications

Pliant Therapeutics, Inc.

<mailto:ir@pliantrx.com>

 View original content to download multimedia: <http://www.prnewswire.com/news-releases/pliant-therapeutics-to-present-data-at-the-liver-meeting-2020-301168419.html>

SOURCE Pliant Therapeutics, Inc.